EXTRA-PC trial: what clinicians have said so far
Combining EPI-7386 With Enzalutamide and Androgen Deprivation Therapy for Metastatic Hormone-Sensitive Prostate Cancer
- NCT06312670 ↗
- Completed
- Pedro Barata, MD, MSc
- Focused size, estimated: 1–150 verified statements once built
Discussed at: 2026 ASCO Genitourinary Cancers Symposium
We haven't built an HCP commentary report on EXTRA-PC (masofaniten (EPI-7386) plus enzalutamide plus androgen deprivation therapy in treatment-naïve metastatic hormone-sensitive prostate cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on EXTRA-PC so far
Podcasts, YouTube videos and posts on X and Bluesky we have indexed that name the trial. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 3 posts on X, typically up to 13 once built |
The trial
ClinicalTrials.gov- Official title
- Phase 2 Trial Combining EPI-7386 With Enzalutamide and Androgen Deprivation Therapy for Metastatic Hormone-Sensitive Prostate Cancer
- Phase
- Phase 2
- Status
- Completed
- Conditions
- Metastatic Hormone-sensitive Prostate Cancer (mHSPC); Prostate Cancer; Prostate Adenocarcinoma
- Interventions
- EPI-7386; Enzalutamide; Androgen Deprivation Therapy (ADT)
- Arms
- EPI-7386 + Enzalutamide · Experimental
- Enrollment
- 13
- Primary outcomes
- Biochemical response rate
- PSA progesterone-free survival (PFS)
- Radiographic PFS (rPFS)
- ORR (confirmed)
- Sponsor
- Pedro Barata, MD, MSc with ESSA Pharma Inc.
- Start
- May 16, 2024
- Primary completion
- Jan 9, 2025
- Results posted
- No
- Registry record
- NCT06312670 · updated May 29, 2025
Publications
linked from the registry- Jang A, Fowler P, Helminiak K, Kumar HLS, Pasucal J, Delong V, Zhong JY, Jindal T, Grier AL, Patel RR, Hislop M, Cesano A, Villaluna K, Younginger B, Wolff K, Richey K, Bray J, Garcia H, Adamowicz T, Reese A, Nizam A, Gupta S, Wee CE, Margevicius S, Fu P, Mendiratta P, Sheng IY, Brown JR, Garcia JA, Barata PC. EXTRA-PC: a phase II trial of masofaniten (EPI-7386) and enzalutamide for patients with treatment-naive metastatic hormone-sensitive prostate cancer. Oncologist. 2026 Jan 17;31(2):oyaf434. doi: 10.1093/oncolo/oyaf434. PubMed 41467749